HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


EC Scientific Committee To Reconsider Preservative MI Use In Cosmetics

This article was originally published in The Rose Sheet

Executive Summary

New data from trade association Cosmetics Europe has prompted the EC’s Scientific Committee on Consumer Safety to take another look at the safety of methylisothiazolinone when used in rinse-off products and leave-on hair products. Previously, the committee’s assessment of the preservative found that there was no safe concentration when used in leave-on cosmetic products.

You may also be interested in...

Podcast: Preservatives Crisis Calls For Marketing Revolution

The cosmetic sector’s shrinking preservative palette calls for a dramatic marketing shift, according to industry veteran David Steinberg of Steinberg & Associates. In a May 11 interview, the cosmetic chemistry expert discussed movement away from proven preservative systems, implications for industry and consumer safety, and options for manufacturers intent on eschewing traditional preservatives, which are few and expensive.

Gemdo Warning Letter Speaks Volumes About FDA Concerns, Industry Challenges

There is much for cosmetic stakeholders to take away from FDA’s April 16 warning letter to Gemdo Cosmetics Inc., which highlights some key enforcement priorities at the agency and topline issues currently facing the industry as a whole.

Cosmetic Adverse Event Reports Spiked 56% In Fiscal 2014 – FDA

According to FDA’s Office of Cosmetics and Colors, the number of cosmetic adverse events reported to the agency reached 491 in fiscal 2014, a 56% increase over fiscal 2013. FDA reps say the agency’s data can be deceptive and the total number likely would be higher if cosmetic adverse-event reporting were mandatory.

Related Content

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts